Cancer is the second leading cause of death globally and is projected to overtake infectious disease as the leading cause of mortality in Africa within the next two decades. Cancer is a group of genomic diseases that presents with intra- and inter-population unique phenotypes, with Black populations having the burden of morbidity and mortality for most types. At large, the prevention and treatment of cancers have been propelled by the understanding of the genetic make-up of the disease of mostly non-African populations. By the same token, there is a wide knowledge gap in understanding the underlying genetic causes of, and genomic alterations associated with, cancer among black Africans. Accordingly, we performed a review of the literature to survey existing studies on cancer genetics/genomics and curated findings pertaining to publications across multiple cancer types conducted on African populations. We used PubMed MeSH terms to retrieve the relevant publications from 1990 to December 2019. The metadata of these publications were extracted using R text mining packages: RISmed and Pubmed.mineR. The data showed that only 0.329% of cancer publications globally were on Africa, and only 0.016% were on cancer genetics/genomics from Africa. Although the most prevalent cancers in Africa are cancers of the breast, cervix, uterus, and prostate, publications representing breast, colorectal, liver, and blood cancers were the most frequent in our review. The most frequently reported cancer genes were BRCA1, BRCA2, and TP53. Next, the genes reported in the reviewed publications' abstracts were extracted and annotated into three gene ontology classes. Genes in the cellular component class were mostly associated with cell part and organelle part, while those in biological process and molecular function classes were mainly associated with cell process, biological regulation, and binding, and catalytic activity, respectively. Overall, this review highlights the paucity of research on cancer genomics on African populations, identified gaps, and discussed the need for concerted efforts to encourage more research on cancer genomics in Africa.
INTRODUCTION

Cancer is the second leading cause of death globally (1). In Africa, cancer incidence and mortality continue to grow rapidly. According to the 2018 Globocan data, new cancer cases and cancer deaths in Africa were estimated at 1,049,800 and 700,800, respectively (2). In 2018, women in East Africa had the highest cumulative risk of dying from cancer globally. The burden of cancer in Africa is increasing, and this burden is expected to increase by 60% by the year 2030. To lower this projected increase in cancer burden, population-relevant biological studies and the identification of innate risk factors among African populations are needed (3–5).

As cancer is a genetic disease, scientific studies investigating its causes, diagnosis, and treatment in developing countries need to focus more on genetics and genomics. The African or Black population is not a homogenous group and, as such, necessitates the need for genomic/genetic studies to reflect the diverse African populations. The population history of Africa shows that the people of Africa are the most genetically and phenotypically diverse population (6, 7). The peopling history of Africa has been described by Campbell et al. and Tucci & Akery (8, 9), and their reviews showed that African ethnic groups and tribes are genetically heterogeneous. Hence, there is likely a critical contribution of the underlying within-group genetic differences to the disparity in cancer prognosis seen among Blacks (10). Therefore, cancer genetics/genomics studies are expected to significantly impact the understanding of the risk, susceptibility, diagnosis, and treatment of this disease.

The genomic heterogeneity of human populations was driven by ancient migration and heterogeneous adaptive pressures on the human genome, particularly on the African Continent (11, 12). These evolutionary events resulted in the split of human populations into five distinct groups: southern Khoe-San, northern Khoe-San, central African hunter-gatherers, West Africans, and East Africans, out of which a subset migrated out of Africa and is now recognized as the out-of-Africa population (11, 12). Therefore, the African continent could be considered to harbor the repository of human genomic diversity and serves as the resource reference for understanding the role of genomics in human health equity. This repository is further deepened by the present-day North African populations enriched with the genetic pool of the out-of-Africa’s Euro-Asian populations. Still, Africa’s contribution to global genetic and genomics information is grossly disproportionate to its population’s diversity and size. For example, very few African populations were included in the HapMap and 1000Genome projects (13). This is a serious shortcoming for a group of people that represent over 90% of human genomic diversity. A recent review of genome-wide association studies (GWAS) showed that Africans (including African Americans) only represent 2.4% of individuals included in all GWAS studies (14).

The proper understanding of genetics and genomics among African populations will expectantly improve prevention, diagnosis, and treatment outcomes of cancer. Although recent evidence shows that the burden of cancer is in Africa, there remains a huge deficit in requisite skills and infrastructure required to carry out the necessary research studies to alleviate this knowledge gap, requiring still non-African nations to fill this gap (15).

Accordingly, in this review, we discuss both genetics and genomics study findings across multiple cancer types in African populations. The goal here is to demonstrate the existing knowledge and to crucially identify the gaps that should be filled in order to address the cancer burden across Africa.

METHODS

The peer-reviewed publications included in this review were extracted from PubMed and covered the period between January 1990 and December 2019, as shown in the flow chart in Figure 1. Since PubMed Medical Subject Heading (MeSH) terms involve synonym control, it yields more precise and inclusive search results (16). Our literature search approach, therefore, utilized an integration of MeSH terms that incorporated “the disease” (neoplasm), 54 African countries, and combinations of study parameters (gene or protein or molecular biology or mutation or genetics or genomics). After extracting African cancer papers, we next filtered those to include only papers pertaining to cancer molecular biology (protein or nucleic acid). Cancer molecular biology papers were then further filtered using “genetic* OR genomic* OR mutation*[MeSH Terms].” The final criteria were that the studies must utilize biospecimens of African origin. Two authors (SOR and OAR) manually verified these publications to ensure the accuracy of terms.

For the purpose of data extraction, the metadata and abstract of each publication returned from our search were collected in a single corpus and subjected to text-mining using the R packages RISmed (17) and Pubmed.miner (18). The publications returned were analyzed in R to identify the cancer types/sites associated with each publication, as described by Acharya et al. (19). Furthermore, the R package “Pubmed.miner” was used for obtaining the names and frequency of occurrence of genes denoted in “Human Genome Nomenclature Committee” (HGNC) symbols (20). For this purpose, we considered the genes reported in the abstract as the genes associated with the most prominent findings of the publications. Next, these genes were pulled and subjected to gene ontology functional profiling for three gene ontology classes (“molecular function”, “biological process”, and “cellular component”) using “goProfiles” (21).

RESULTS

The total numbers of publications returned by our search on the topics of cancer globally, as well as cancer, cancer molecular biology, and cancer genetics/genomics within Africa between 1990 and December 2019, are shown in Figure 1. Out of nearly two and half million publications on cancer globally, only 7,697 (0.329%) papers were returned by our search on cancer in Africa, with only 1,456 (0.061%) related to molecular biology (protein or nucleic acid). Of these publications, only 375 articles were found using the search terms “genetic, genomics, mutations”.
Among all cancer publications pertaining to Africa, the cancer sites with the highest number of published studies represented cancers of the cervix, breast, liver, head/neck, and colorectal while, lung, brain, bladder, ovarian, and uterine cancers were the least frequently reported on (Figure 2A). For publications related to cancer molecular biology in Africa, breast, liver, colorectal, blood, and prostate cancer were the most frequent. In contrast, cancers of the brain, stomach, lung, skin, and uterine cancer had the fewest publications (Figure 2B). Most papers reporting cancer genetics or genomics reported on breast, colorectal, liver, blood, and ovarian cancer, with the fewest cancer genetics or genomics studies on the brain, stomach, lung, skin, and uterine cancers (Figure 2C).

There were also disparities in the publications by country, as illustrated in Figures 3A–C. Nigeria had the most papers on cancer overall, followed by South Africa, Egypt, Tunisia, Morocco, and Kenya (Figure 3A). For cancer molecular biology papers, Egypt took the lead, followed by Tunisia, South Africa, and then Nigeria (Figure 3B). Tunisia, however, returned the most search results for cancer genetics/genomics papers followed by Egypt, South Africa, and Morocco (Figure 3C). Overall, only seven African countries contributed at least 10 cancer genetics/genomics publications, while 22 African countries returned no search results on cancer genetics/genomics studies. The search results show clear evidence of regional differences in publishing capacity, with North Africa and South Africa leading in cancer research.

Next, we focused specifically on the list of 375 genetics/genomics publications for gene curation and review. We did this to identify the functional contributions of these studies to the understanding of biological processes associated with carcinogenesis, using functional correlations comparison (22). A total of 152 genes in the abstracts of 375 publications on cancer genetics were extracted and further annotated into the following gene ontology classes: cellular component, biological process, and molecular function (Figures 4A–C). In the cellular component class, the genes studied were mostly associated with cell part, organelle, organelle part, and cell membrane. In contrast, the genes in the biological process were mainly associated with cell process, biological regulation, response to stimulus, and positive regulation of the biological process. The molecular function ontology genes were mostly associated with binding, catalytic activity, molecular function regulator, molecular function transducer activity, and transcription regulation in the molecular function class, which are dysregulated in cancer. The most studied genes in the publications were BRCA1, BRCA2, TP53, EGFR, and MLH1 (Table 1), indicating a dearth of data on the plethora of other
critical cancer-associated genes. Next, we reviewed some of the key findings reported across the 375 genomics papers for each of the major and most frequently published cancer types below.

**Breast/Ovarian Cancer**

Breast cancer has continued to be the leading cause of cancer morbidity and mortality in Africa, with an incidence and mortality rate of 37.9 and 17.2 per 100,000, respectively, according to GLOBOCAN 2018 data (2). Breast cancer’s prominence in Africa dates back to around 3000 BC in the ancient Egyptian medical text - the Edwin Smith Papyrus, the oldest cancer record (23, 24). Not surprisingly, breast cancer had the highest number (n=82, 19%) of peer-reviewed cancer genetics/genomics publications in Africa. With the current understanding of cancer as a genomic disease and the unique phenotype that breast cancer presents in the people of African ancestry, attempts to address its burden require rigorous genomics investigations.

Together with cancer of the ovary, breast cancer risk is greatly increased in women with inherited mutation(s) in tumor suppressor genes (25). Not surprisingly, the earliest publications on breast and ovarian cancers in African populations focused on understanding the contribution of variations in the tumor suppressor genes *BRCA1/2* and *TP53*, particularly in North African populations of Morocco, Tunisia, Egypt, and Sudan (26–40). While these findings hold immense benefits for those populations, their *BRCA* variants are not dissimilar to those present in the out-of-Africa populations.
FIGURE 4 | Gene ontology of the genes reported in the abstracts of publications on cancer genomics in Africa. (A) Cellular component ontology, (B) Biological process ontology, and (C) Molecular function ontology.
This, therefore, limits the translational impact of such findings to controlling breast/ovarian cancer in the Sub-Saharan African populations.

Furthermore, the major epidemiological implication of BRCA mutations lies in identifying specific founder mutation(s) within each population, with the view of using it as a predictive molecular risk marker and treatment recommendation. For instance, advances in understanding the role of BRCA proteins in tumorigenesis have now led to improved therapeutic choices with the availability of PARP inhibitors for breast cancer patients with germline mutations (41). Also, the identification of founder BRCA gene mutations in populations like Ashkenazi-Jewish (Hungarian and Russian), Polish, Norwegian and Icelandic people has resulted in improved low-cost genetic testing and the determination of high-risk individuals for breast and ovarian cancers (42, 43). Therefore, these have made it imperative for the founder mutations of the BRCA gene within Africa populations to be identified and included in breast cancer screening, diagnosis, and treatment.

In an attempt to consider BRCA contributions to breast cancer in Africa, Rebbeck et al. (44) published a global distribution of BRCA1 and BRCA2 germline mutations by including women from Nigeria and South Africa. However, the extent to which their subjects represent the ethnic and genetic diversity in these countries is unclear. They did note that the mutations observed in African American families were of African origin because they are unlike the mutations seen in other out-of-African ethnic groups (44–46). This study of Rebbeck et al. (44) was part of the Consortium of Investigators of Modifiers of BRCA1/2 investigations, which only included the nation of South Africa (http://cimba.ccge.medschl.cam.ac.uk/cimba-groups/study-groups/). A more detailed study of Zheng et al. (47) on Nigerian women established that up to 20% of inherited invasive breast cancer cases in Nigeria are associated with inherited mutations in BRCA1, BRCA2, PALB2, or TP53. Their findings on BRCA1 and BRCA2 built on the earlier report of Fackenthal et al. (48) that Nigerian breast cancer patients have a very high frequency of BRCA1 and BRCA2 mutations. These mutations were reported by Pitt et al. (49) to be associated with greater structural variation and aggressive biology in Nigerian women with HR+/HER2− tumors. Similar findings were reported by Pegoraro et al. (50) in Black South Africans with ovarian epithelial malignancies.

Recently, Mahfoudh et al. (51) showed that the 5382insC BRCA1 mutation contributes to the development of triple-negative breast cancer (TNBC) in Tunisia. The higher mortality of breast cancer in women of West African ancestry is due in part to higher levels of TNBC (compared to whites), which is associated with the poorest prognosis of all breast cancer subtypes. Hence, BRCA screening in Africa could help identify women who can benefit from PARP inhibitors leading to improved clinical outcomes. In South Africa, Reeves et al. (52) characterized BRCA1 mutations in breast and/or ovarian cancer to identify founder mutations in Afrikaner families. However, this population is also of European ancestry, and the mutations that were identified were similar to those reported in the Netherlands and in Ashkenazi Jews (53). They also reported that variants of PALB2, a partner and localizer of BRCA2 was also associated with the early onset of breast cancer in some South African patients (53). PALB2 functions as a scaffold between BRCA1 and BRCA2. Similar PALB2 mutations have previously been identified in women of European ancestry but not in women with Nigerian ancestry, as reported by Sluiter et al. (54).

The first publication on BRCA mutations in the indigenous Sub-Saharan African population was by Zhang et al. (55), who identified an ancient BRCA1 mutation (Y101X) in Yoruba (Nigeria, West Africa) breast cancer patients. The team further reported a non-pathogenic novel exon 21 deletion of BRCA1 (c. 5277 + 480_5332+672del) in Nigeria in addition to a novel deleterious BRCA1 mutation (c. 1949_1950delTA) in a woman from Senegal (West Africa) (56). Another novel founder, BRCA2

---

**TABLE 1 | List of top 20 genes reported in the abstracts of publications on cancer genetics and genomics in Africa.**

| Gene symbol | Genes | Frequency |
|-------------|-------|-----------|
| BRCA1       | breast cancer 1, early onset | 164 |
| BRCA2       | breast cancer 2, early onset | 108 |
| TP53        | tumor protein p53 | 73 |
| EGFR        | epidermal growth factor receptor | 53 |
| MLH1        | mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) | 41 |
| KRAS        | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 39 |
| BRF1        | v-raf murine sarcoma viral oncogene homolog B1 | 30 |
| XPA         | xeroderma pigmentosum, complementation group A | 29 |
| RET         | ret proto-oncogene | 22 |
| NPM1        | nucleophosmin (nucleolar phosphoprotein B23, numatin) | 21 |
| NLRP7       | NLR family, pyrin domain containing 7 | 20 |
| APC         | adenomatous polyposis coli | 19 |
| JAK2        | Janus kinase 2 | 19 |
| MSH2        | mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) | 19 |
| ABCB1       | ATP-binding cassette, sub-family B (MDR/TAP), member 1 | 16 |
| GSTT1       | glutathione S-transferase theta 1 | 16 |
| MGMT        | O-6-methylguanine-DNA methyltransferase | 15 |
| RB1         | retinoblastoma 1 | 15 |
| WT1         | Wilms tumor 1 | 15 |
| MDM2        | MDM2 oncogene, E3 ubiquitin protein ligase | 14 |
mutation, was identified by var der Merwe et al. (53) in the Bantu-speaking Xhosa population (South Africa). Other studies have identified new BRCA mutations and their contribution to early-onset and sporadic breast and/or ovarian cancer in Arabic speaking countries (57) of Egypt (58), Tunisia (51, 59–66), Algeria (67–69), Morocco (70–72), and Sudan (73, 74), in addition to Senegal (75), Mauritius (76) and South Africa (50, 77–79) in the Sub-Saharan region.

Additional studies on BRCA genes have expanded to identifying the population-based mutation frequency and screening/genetic testing in the Democratic Republic of the Congo (80), Morocco (81), Tunisia (82, 83), Algeria (84, 85), familial studies in Morocco (86, 87), and large genomic rearrangement in Egypt (88, 89). Of these, the contribution of BRCA mutations to male breast cancer was reported only in the Moroccan study by Guoua et al. (86). A mutation in the TP53 gene often accompanies BRCA mutations in breast and ovarian cancers, making the mutations in these DNA repair genes relevant in therapeutic interventions (90, 91). The publications on TP53 mutation have focused on its expression in breast cancer and the contribution of its polymorphism, particularly codon 72 to breast cancer (28, 31, 33, 36, 92–94), as well as to its interaction with MDM2 344T>A. A polymorphism in response to chemotherapy of breast cancer in Tunisia (95). Other DNA repair genes that have been studied in Africa include XRCCI and XPD in Egypt (96, 97). Overall, even though it is one of the most studied genes in African cancer research, there remains a very small number of publications on BRCA mutations in the indigenous African population, clearly showing a knowledge gap on a hereditary gene critical in managing incidence and clinical outcomes in breast cancer.

Exogenous factors that drive DNA damage include viruses and xenobiotics. The presence of these agents and genetic alterations that mediate the ensuing host-response can promote carcinogenesis. The first reports of virus-associated breast cancer in Africa were by Levine et al. (98) and Hachana et al. (99), who reported the presence of a human breast carcinoma virus (a virus similar to mouse mammary tumor virus) in 74% of tumors in Tunisia. These were the only two studies that reported this virus in Africa. Studies have also shown an association of the hepatitis C virus in Egypt (100) and Human papillomavirus (HPV) in Rwanda (101) to breast cancer progression. However, the most reported virus linked to breast cancer in Africa is the Epstein-Barr virus (EBV), with studies published in Algeria (102), Eritrea (103), Egypt (104), and Sudan (105). EBV was the first identified human oncogenic virus that was detected in Uganda in 1964 by Denis Parsons Burkitt (106–108) and its molecular pathogenesis has been reviewed by Lawson et al. (109). The virus is responsible for many cancers across the continent, and the host genomic factors that facilitate tumorigenesis are described below.

The detoxification of carcinogenic chemical entities is primarily catalyzed by cytochrome P450 (phase I) and a host of phase II xenobiotic-metabolizing enzymes. Polymorphisms in these genes dictate, in large part, the effect of xenobiotics on the biological system. Such polymorphisms have been reported in CYP1A1 and CYP1B1 in Nigeria and Egypt (110, 111), CYP2D6 in South Africa (112), and CYP1A2 in Tunisia (113). Furthermore, as hormone-responsive cancers, these cytochrome P450 genes play critical roles in estrogen metabolism and the response of the tumor to endocrine therapy. For genes coding for phase II xenobiotics metabolizing enzymes, the deletion of GSTT1 and GSTM1 were reported by Khedhaier (114) to predict the early onset and prognosis of breast cancer among Tunisian women. The number of TA repeats in the promoter of low activity UGT1A1 was reported to be protective against breast cancer in pre-menopausal Nigerian women (115, 116). Similarly, the association of polymorphisms in paraoxonase, cyclooxygenase, glyoxalase, and glutathione peroxidase genes with breast cancer were reported in Egypt and Rwanda (117–120).

Inflammation is a major hallmark of cancer, and it is known to contribute to aggressive tumor biology. This makes understanding the variations in immuno-oncogenic genes important in understanding the population biology of cancer in Africa. Mestiri et al. (121, 122) reported that polymorphisms in TNF-α and TNFR II increase the susceptibility to breast cancer in Tunisian women, with TNFR1 -196R prevalent in premenopausal women. Conversely, FASL (rs763110) was associated with a good prognosis in the same population (123). However, HLA-DQB1 and HLA-G +3142C>G (rs1063320) polymorphisms were related to increased breast cancer susceptibility (124, 125). Pathogenic polymorphisms of other inflammatory genes like NFE2, IL1α, IL1β, IL6, IL8, and CXCR2 have also been identified in Tunisian and Egyptian breast cancer patients (126–130).

Recent evidence suggests that inflammation-driven cancer in Blacks is influenced by vitamin D levels (131, 132). To establish the association of vitamin D variants and related genes with breast cancer, El-Shorbagy et al. (133), Abd-Elsala et al. (134) and Shaker & Senousy (135) showed that polymorphisms in the vitamin D receptor (VDR) increases the risk of breast cancer in Egyptian women who carry the ATT haplotype. The risk of developing breast cancer due to these mutations was elevated in women who also carry RANKL (rs9533156), OPG (rs2073617), and CHI3L1 (rs4950928) (135). Similar studies have also reported the risk allele in Ethiopian women as VDR rs2228570 (FokI) (136) but the study of Wang et al. (137) did not identify variants in vitamin D related genes as risk factors for breast cancer in Nigerian women that were used as the ancestral population for African American women. This genome-wide association study, however, identified TYPRI (rs41302073), a melanin synthesis regulatory gene, as a significant risk allele for breast cancer in their dataset that included African American and Barbadian women. Furthermore, the authors also used the same dataset to identify WWCI as an important susceptibility locus in the Hippo pathway for breast cancer (138).

Polymorphisms in the angiogenesis-associated genes have also been identified in breast cancer in African populations and include the LEP, LEPR, VEGF, and MMP2. leptin and LEPR Q223R (rs1137101) were identified as risk factors for breast cancer in Egyptian and Nigerian women (139–141).
while leptin alone was notably reported as a key driver of breast cancer progression through the induction of JAK/STAT3, ERK1/2, and estrogen pathways in obese Egyptian women (142). Furthermore, variants of VEGF and MMPs, which induce the upregulation of these genes, were reported as risk factors in North African countries of Morocco, Egypt, and Tunisia (143–148). Other overexpressed angiogenic proteins reported are EGFR in Tunisia (149) and IGFBP2 and IGFBP5 in Nigerian women (150). The authors proposed these angiogenic proteins as druggable targets in breast cancer treatment. Another therapeutic pathway that has been studied is the PIK3/AKT pathway. Jouali et al. (151) reported PIK3CA hotspot mutations in 13% of triple-negative breast cancer cases in Morocco. They suggested that this pathway could be of therapeutic importance for triple-negative breast cancer in Morocco.

Cancer is a polygenic disease, and scientific investigation to understand breast cancer’s population biology, therefore, cannot be simplified to a single genetic variant. Hence, techniques to investigate multiple genes at a time such as with next generation sequencing are now being utilized to understand the genetic risk factors of breast cancer in Africa. To that effect, genome-wide studies (GWAS) published primarily on breast cancer in African populations include GWAS in Tunisia and South Africa (152–154) and whole-exome sequencing in Tunisia and Egypt (155–157). In the Tunisian population, Shan et al. (154) and Hamdi et al. (152) identified rs1219648, rs2981582, rs8051542, rs889312, and rs889312 as breast cancer susceptibility single nucleotide polymorphisms (SNPs), with rs9911630 as the SNP with the strongest effect on the expression of BRCA1 and two long non-coding RNAs (NBR2 and LINCO08854). The genome-wide copy number alteration analysis of breast cancer in South African women (153) identified the amplification in Xp22.3 and 6p21-p25, and other regions that affect known cancer genes like CCND1, CDKN1A, MDM2, TP53, and SMAD2. Meanwhile, the whole-exome sequencing study by Hamdi et al. (152) and Riahi et al. (156) linked breast cancer in Tunisian women to alterations in MMS19, DNAH3, POLK, KTAP6, and RCC1 in BRCA1/2 mutation-negative patients with familial breast cancer. A similar study in Egypt also found other novel genetic variants responsible for familial breast cancer. These genetic variants are different from those linked to DNA damage repair (like BRCA1 and BRCA2) but are linked to other functional genes like NBP8F10, ZNF750, CHT15, NPIP1B11, and PHIP, that are involved in RNA binding, transcriptional regulation, extracellular matrix, a structural protein, and signal transduction, respectively.

The contribution of epigenetic factors to risk and prognosis of breast cancer reported in Africa included the roles of tissue microRNA, circulating free mRNA, circulating long non-coding RNA (158–163) as well as DNA methylation status of breast cancer susceptibility genes like APC, ERα, RASSF1A, UCHL1, COX-2, and FHIT (161, 164–167) in breast tumor across Africa.

**Prostate Cancer**

Prostate cancer continues to be the leading cause of cancer morbidity and mortality among African men (168, 169). Although genetics is a major risk factor for this disease, there are only a few publications on prostate cancer genomics in Africa. In this subsection, we review 14 papers that were relevant to prostate cancer out of the list of 375 papers extracted. Prostate cancer presents with an aggressive phenotype among men of African descent, and like breast cancer, it is a hormone-responsive tumor. Consequently, early studies on this disease identified androgen’s influence in the control of normal prostate growth and, in its transformation into adenocarcinoma, a phenomenon called the “androgen hypothesis” (170, 171). Therefore, peer-reviewed publications on prostate cancer genetics in African populations have reported genetic variants that contribute to elevated circulating androgens, including androgen reduced clearance and upregulated activity of androgen receptor. These include the polymorphisms in cytochrome P450 genes like CYP3A4, CYP3A5, CYP1A1, CYP17 in Morocco, Tunisia, Nigeria, South Africa, and Senegal (172–176). Besides, alterations in CAG and GGN repeats in the androgen receptor gene have been reported as risk factors in North Africa, Ivory Coast, and Nigeria (177, 178). Unlike the North African populations, prostate cancer in Sub-Saharan African populations and North African Berbers were associated with high frequencies of low size alleles (CAG under 18 repeats, and GGC under 15 repeats) (178). Other reported genetic variations that increase African populations’ susceptibility to prostate cancer include GSTM1, GSTT1, UDP-glucuronosyltransferase, and sulfotransferase in Tunisia and Algeria (179–182).

A deeper understanding of the disease’s polygenic risk was elucidated by four studies that have investigated the genome-wide genetic variations in prostate cancer across Africa. These included GWAS of prostate cancer in Tunisia, Ghana, and Uganda (183–185), as well as a whole-genome sequencing of six individuals in South Africa (186). It is interesting to note that these four studies did not identify any common high-risk prostate cancer variants. The Tunisian study identified three regions (on chromosomes 9, 17, and 22) containing 14 significant SNPs, three of which are shared with Caucasian populations (185). The Ghanaian study of Cook et al. (184) identified 30 most significant SNPs distributed across chromosomes 1, 2, 3, 5, 6, 7, 8, 9, 10, 13, and 20.

Meanwhile, the Ugandan study identified risk alleles on chromosomes 1, 6, 11, 13, 14, and 17 (183). Although the Ugandan and Ghanaian populations shared cytoband 6p21.32 in common, the nucleotide positions and risk alleles were still different. This chromosome position codes for HLA-DQB1, which has been reported to be important for the adaptation of African ancestral populations to the African rainforest environment. These studies further add to the existing evidence of the heterogeneity of African populations (12) and that cancers in these populations may have a different biology. These findings provide further evidence for the need to disaggregate the Black population by genetic lineage in studying the contributions of genomics to racial disparities of diseases like prostate cancer. Importantly, it is yet to be revealed whether these differences influence the disease phenotype and disparity in outcome.
The most commonly reported genomic alteration that drives prostate tumorigenesis is TMRPSS2-ERG fusion, and this androgen-upregulating fusion is known to correlate with higher grades of the disease. Although men of African ancestry are known to present with higher disease grade, only three studies have examined the TMRPSS2-ERG fusion on the Continent (187–189). This fusion often results from either a chromosomal translocation or an interstitial deletion, and these studies reported rates that were less than 20% in Ghanaian and Black South African patients (187–189).

Liver Cancer

According to the 2018 GLOBOCAN data, hepatocellular carcinoma accounted for 8.4 cases per 100,000 and 8.3 deaths per 100,000 globally (2) and it is the 4th most common cancer in Africa. We retrieved 46 publications that studied liver cancer genetics/genomics in Africa. Several of these studies investigated the contribution of the hepatitis virus and mycotoxins to this malignancy. These biotic and abiotic agents represent the major causes of this disease on the continent (190, 191). Hence, a preponderance of publications on liver cancer in Africa focused on understanding the contribution of mutation and expression of TP53, and other tumor suppressors like TP73, RB, KLF6, and CTNNB1, to liver carcinogenesis (190, 192–207), particularly in Senegal, Gambia, Nigeria, South Africa, Egypt, and Morocco. These studies identified the mutation in codon 249 of TP53 as a genetic risk factor for developing hepatocellular carcinoma following exposure to either the hepatitis virus or mycotoxins (see Lin et al. [208] for detailed mechanism). In Morocco, MDM2 309 T>G was associated with liver cancer (209, 210). These mutations are known to upregulate this oncogene’s expression, which in turn binds p53 and prevents its tumor suppression function (209) resulting in increased genomic instability as demonstrated by loss of heterozygosity in chromosome 4-q13 in Black South Africans (211).

The development of hepatocellular carcinoma is often preceded by chronic inflammation of the liver. In Africa, hepatic inflammation is exacerbated by high-prevent comorbid conditions like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and liver cirrhosis. For instance, the prevalence of NAFLD in Nigeria, Ethiopia, and South Africa has been reported to be 68.8%, 73%, and 87%, respectively (212).

Despite the pervasiveness of liver cancer across Africa, only the Egyptian and Tunisian populations have been studied for the contribution of variation in inflammation-related genes to this disease. These studies reported mutations in IL1R, IL17A, IL8, IL1, IL16, IL12, IL27, and TNF-α as risk factors for hepatitis and hepatocellular carcinoma (213–219).

Other authors have focused on the development of biomarkers for liver cancer, using epigenetic factors like microRNAs. These include serum Mir-224, Mir-215, Mir-143, Mir-122, Mir-199a, and Mir-16 (220, 221). Specifically, Mir-122 and Mir-222 levels were reported by Motawi et al. (222) as a discriminating biomarker for distinguishing liver injury from liver cancer. This group further reported that LncRNA HULC rs7763881 and MALAT rs619586 were associated with decreased susceptibility of Egyptian hepatitis virus-persistent carriers to liver cancer (223).

Mycotoxicosis, with concomitant early-life protein malnutrition, is an important driver of liver cancer in Africa (224–226). One group of enzymes that are involved in detoxifying mycotoxins are the glutathione-S-transferases (μ, θ, π, α, σ). Hence, individuals who do not express all the enzymes due to homozygous deletion are more susceptible to myco-carcinogens (227). Overall, two studies have identified the deletion of GSTM1 and GSTT1 haplotypes as risk factors for aflatoxin-associated hepatocellular carcinoma (228, 229) in Africa.

The last group of genes that have been studied on hepatocellular carcinoma in Africa are those involved in angiogenesis, including VEGF, MMP, RASSF1A, and RECK. In Egypt, Samamoudy et al. (230) reported that patients with MMP9 (rs3918242) are at high risk of developing liver cancer while RECK (rs12814325) (231) could account for the disease progression and metastasis.

Cervical Cancer

Cervical cancer continues to be responsible for the highest cancer mortality in Africa, accounting for 2,000,000 deaths in 2018 (2), and its incidence rates continue to increase in most Sub-Saharan African countries (232). However, studies on cervical cancer genetics/genomics only represented 3% of the publications we retrieved. Similar to liver cancer, cervical cancer is viral-related and primarily caused by Human Papillomavirus (HPV). Several reviews have discussed the burden, distribution, and contribution of HPV serotypes to cervical cancer in Africa (233–235). Despite the burden of HPV in Africa, only a small proportion of women that are infected develop cervical cancer (236, 237). It is, therefore, essential to understand the genetic factors that contribute to the risk of progression from HPV infection to cervical cancer across Africa.

One of such genetic factors that increase susceptibility to HPV-associated cervical carcinogenesis is the TP53 R72P mutation (238), which was reported in Gabon, Senegal, Sudan, Morocco, and South Africa; and this risk increases when combined with the chromosomal allelic loss of RB or with aberrant methylation of DAPK1, RARB, TWIST1, and CDH13 (79, 239–244). Furthermore, aberrant methylation of these genes was proposed by Feng et al. (245) to be useful in Senegal for the screening of cervical cancer, either alone or in combination with cytology. The importance of this homozygous arginine polymorphism at codon 72 of TP53 in determining genetic susceptibility of a population has been shown in Israeli Jewish women who have been reported to have reduced susceptibility to HPV-associated cervical cancer (246).

The variations in genes involved in inflammatory and apoptotic response pathways have also been reported to increase African women’s susceptibility to cervical cancer (247). The reported polymorphisms in Africa include those of TLR2 3/4/9 and IL1/10/15 genes in Tunisia and -308 promoter polymorphism of TNF-α in South Africa (248–250). Meanwhile, polymorphisms in FASR-670A and CASP8-652 were associated with a reduced risk of developing cervical cancer in South African women (251).
Colorectal Cancer

Colorectal cancer is the 5th most common cancer in Africa and accounted for 550,000 deaths in 2018 (2). We retrieved 56 publications on colorectal cancer genetics/genomics from Nigeria, Ghana, South Africa, Algeria, Tunisia, Morocco, and Egypt. The findings in these publications included: (1) the identification of I130K APC polymorphism in the indigenous Black population in South Africa and Tunisia to development of familial adenomatous polyposis coli (252–255), (2) the presence of mutations in the MUTYH, MLH1, and MSH2 gene in patients with colorectal cancer and attenuated polyposis in Algeria, Egypt, Morocco, Tunisia, and South Africa (256–266), (3) the burden of KRAS and BRAF mutations in colorectal cases in Morroco, Nigeria, Ghana, Egypt and Tunisia (267–275) and (4) the level of microsatellite instability in South African, Nigerian, Ghanian, Tunisian, and Moroccan colorectal cancer patients (259, 271, 274, 276–281). Other studies have also explored the contribution of epigenetic changes to colorectal cancer carcinogenesis in Africa (278, 282–285). For example, the methylation of UCH1 and p14ARF genes were reported to drive colorectal cancer in the presence of TP53 mutation in Tunisia (282, 283, 286, 287). Other studies on the North African populations reported the influence of polymorphisms in telomere and mitochondrial D-loop region on the clinicopathological characteristics of the colorectal cancers among their patients (288, 289). Hence, the dearth of data on the genomics of this disease makes it difficult to explain the increase in the level of sporadic colorectal cancers reported in African countries, despite the difference in lifestyle and dietary habits. Profiling of these genes, including the use of targeted next-generation sequencing, in the screening and clinical management of this disease is essential in reducing its burden (255, 290).

Lung Cancer

Across Africa, lung cancer ranks 6th with about 550,000 cases in 2018 (2). However, the burden of this disease is on the North African countries and South Africa (2). This burden reflects the pattern of tobacco smoking reported through national surveys (291). Lung cancer genetics/genomics studies have also largely been conducted on the North African populations of Tunisia and Egypt. These studies investigated the role of angiogenic pathway genes like EGFR and MMP-3 in lung carcinogenesis (292–297). The expression of EGFR was associated with poor prognosis, and the frequency of the mutations observed in Tunisian and Moroccan patients was similar to those of Europeans (294, 296, 298). However, Dhieh et al. (292) found that normal p53 expression in these patient populations was much less frequent than in Europeans. Similarly, a nonsense mutation (Arg-196-TERM) in exon 6 of TP53 was identified in the small cell lung cancer from gold miners in South Africa (299).

Cigarette and air pollution are major sources of lung carcinogens; hence, studies have reported polymorphisms in CYP1A1, CYP1A2, CYP2F1, CYP2A6*2, and CYP2A6*9 (300–305) in lung cancer patients in North Africa. These polymorphisms alter the detoxification rate of toxicants, and individuals who carry the slow metabolizer variants have an increased risk of lung cancer (300). For example, Hussein et al. (302) concluded that Egyptian smokers with CYP1A1 m1 (rs4646903) and CYP1A1 m2 (rs1048943) are more likely to develop squamous cell carcinoma. Furthermore, lung carcinogens are highly inflammatory and studies in Tunisia, for example, identified alterations in inflammatory genes-TNF-α, IL8, IL17A, IL17F, CCR2, and VDR Fok1 (rs2228570) and Apal (rs7975232) that predispose to lung cancer (306–310).

There were additional studies that used epigenetic techniques to develop diagnostic or prognostic markers for non-small cell lung cancer in Egypt. These included the study of Haroun et al. (311) that identified FHIT methylation and that of Hetta et al. (312) which reported circulating microRNA-17 and microRNA-22 as potential biomarkers for early detection of lung cancer.

Bladder Cancer

Chronic inflammation with attendant oxidative stress induced by *Schistosoma haematobium* infection remains a major cause of bladder cancer in Africa (313–315), with squamous cell carcinoma being the most common (316, 317). Schistosomiasis (or bilharzia) is a neglected tropical disease that is widespread across Africa (318). This cancer is the 10th most prevalent cancer in Africa and accounted for 240,000 death in 2018. Studies on its genetics/genomics represented about 3% of the publications that we reviewed.

Its pathogenesis involves the bladder infection by *S. haematobium*, which induces the formation of carcinogenic N-nitrosamine that contributes to squamous cell carcinogenesis (319), particularly in individuals with TP53 mutation (320). In addition, mutations in genes associated with inflammation and detoxification of carcinogenesis are critical risk factors. One of which is the polymorphisms in CYP2D6 and CYP1A1 that have been studied in Egypt and Tunisia (321–323) and that of CYP2D*1A, which was found to increase the risk and clinicopathological outcome of both transitional and squamous cell carcinomas in Egypt (322). Similar findings were reported in the same North African countries for individuals with GST null genotypes and NAT*5 (341T>C) (324–331).

The neoplastic transformation and progression of bladder cancer are enhanced through oxidative stress-induced genomic instability and chromosomal aberrations, which particularly involve the loss of heterozygosity on chromosomes 8 and 9 (332–338). These aberrations, coupled with p53 and p16 loss, have been reported in both bilharzial and non-bilharzial bladder cancer in Egypt and Tunisia (36, 332, 339–343).

The pattern of CpG island hypermethylation was studied by Gustierrez et al. (344) and they showed that the Schistosoma-associated tumors in Egyptian patients had higher hypermethylation of genes like E-cadherin, DAP-kinase, TP14, TP15, TP16, APC, GSTP1, and TP73. Other authors have further proposed using these unique epigenetic modifications for the early diagnosis of bladder cancer by utilizing plasma circulating microRNA and urinary DNA methylation profile (345, 346).

It is important to note that pesticides have also been implicated in bladder tumorigenesis (347, 348) through...
oxidative stress and KRAS mutation in Egyptian occupationally-exposed individuals (347).

**Other Solid Tumors**

Studies in South Africa, Egypt, Sudan, and Tunisia identified the EBV as the major cause of head and neck cancer (349–354). The genetic risk factors that have been reported include TP53 mutations in Sudan and Egypt (355–357), XRCC1, TNF-α, IL10 promoter, CYP1A1, CYP2D6, and NAT2 polymorphisms in Tunisia (358–361) as well as genome-wide aberrations associated with chromosomes 2p, 3p, 5q, and 18q and microsatellite instabilities (362–364) and mutations in the mitochondrial D-Loop region and Cytochrome b gene (365).

The genomic studies on the cancer of the brain, kidney, pancreas, and other organs are still emerging with very limited publications (366–378). The emphasis of these publications on the polymorphisms of genes associated with inflammatory response is an indication of the importance of this biological process to the neoplastic transformation of normal tissue and the progression of the malignancy. In addition, studies on retinoblastoma concentrated on identifying the constitutional mutations in RB within the North African populations (379–382) while publications on esophageal and gastric cancers focused on identifying the role of RAS genes mutations as drivers of genomic instability (383–386).

**Lymph and Hematological Malignancies**

The most prevalent lymphoma in Africa is Burkitt lymphoma. Its pattern and geographical spread are similar to that of malaria and ancient human migration on the continent (387–392). This aggressive pediatric B-cell non-Hodgkin lymphoma is caused by the EBV, which induces genomic instability in the B-cell that results in hyperproliferation (393, 394) and it is associated with unique TP53 mutations that are clustered between codons 213 to 248 (395–397).

Other studies on lymphoma include: (1) the role of TP73 and FOXP3 in the pathogenesis of reactive lymphoid hyperplasia and diffuse B-cell lymphoma, as well as the contribution of HLA-G polymorphism to non-Hodgkin lymphoma in Egypt (398–400), (2) susceptibility of individuals with A/A genotype of TNF promoter (-308A/G) to non-Hodgkin lymphoma in Tunisia (401) and Egypt (402) and the identification of HLA-B*18, DRB1*03, DRB1*07, and DQBI*02 as lymphoma susceptibility loci in Algerian children (403).

Studies from Egypt, Tunisia, and Morocco have identified the susceptibility or prognostic implications of mutations in FLT3-ITD, NPM-1, KIT, NPM1, HFE, DNMT3A, TERT, and NRAS in hematological malignancies (404–410). NRAS G12D and NRAS G13C mutations were reported in Nigerian leukemia patients Anyanwu et al. (411).

**DISCUSSION**

In order to provide an overview of research progress in African cancer genomics with the view of identifying the critical gaps, we searched and reviewed publications on cancer genetics and genomics in Africa. The 375 publications on cancer genetics/genomics retrieved on PubMed represented only 0.016% of total publications on cancer globally.

According to the 2018 GLOBOCAN data on cancer in Africa, the most frequently diagnosed cancers were breast, cervix, prostate, liver, and colorectum, while the leading causes of cancer deaths were from cancers of the cervix, breast, prostate, liver, and colorectum (2). However, of the top ten frequently diagnosed cancers and the leading cause of cancer deaths in Africa, only breast, colorectal, liver, and ovarian cancers were proportionately represented in cancer genetics/genomics studies returned from search terms.

Overall, Africans are grossly underrepresented in cancer genomics and molecular biology research globally. For example, research on prostate cancer in African men or breast cancer in African women, both leading causes of death in Africa, are still understudied compared to cancers in their non-Black and white counterparts (412).

Although Africa seems to be on the right track in terms of focusing on some of the top cancers, researchers and funding agencies, need to elevate and prioritize genetics and genomics research on cancers that remain hugely underrepresented or unrepresented in the literature for which there is a significant burden in Africa. These include cancers of the lung, ovary, stomach, bladder, prostate, and non-Hodgkin lymphoma, which are among the leading ten causes of death but remain understudied in the literature. Filling this research gap is essential to improving awareness, prevention, diagnosis, and treatment outcomes for people affected by cancer across the continent.

It is also worth noting that most studies on cancer in Africa are clustered to a few regions, mainly North Africa, Nigeria, Ghana, and South Africa. Most of the continent lacks any appreciable data, is often excluded from research efforts, and is devoid of the infrastructure and resources needed to contribute to cancer genomics/genetics discoveries.

It is important to reiterate that this review was based on publications that were indexed in Pubmed only. This is because Pubmed is considered as the most reputable index for biomedical publications, and the data we have retrieved are a good representation of the spectrum and scope of this review. It is also possible that our search did not retrieve some studies that included African populations, and this could be because those studies were not focused on African countries or groups but have used them for comparative purposes, thereby making the data obscure and less prominent in their findings. The use of MeSH terms ensured that relevant publications were extracted from Pubmed.

**CONCLUSION AND FUTURE DIRECTIONS**

As presented in this review, the preponderance of the peer-reviewed publications on cancer genomics in Africa was on the North Africa populations. Hence, there is a need for a concerted effort to address the gaps in the contribution of genomic variance and alterations to cancer in Sub-Saharan African populations.
Recently, Durvasula and Sankararaman (413) reported the presence of ghost archaic introgression into the genome of Sub-Saharan Africa populations, and some of this introgression included regions involved in carcinogenesis. This and the details presented in this review lay credence to the inadequacy of the use of predominantly Caucasian genomics data for cancer control in Africa. The use of personalized medicine and targeted therapy in cancer management rely on understanding the genomics of the population. Hence, there is a need to step up cancer genomics studies for Africa to benefit from medical advances. Also, because Africa is the root of humanity, understanding the genetic basis of this disease in Africans will contribute to improving cancer health equity globally.

In addition, scientific investigations on cancer racial disparity have largely considered the Black race as a homogenous group. However, the evidence is now emerging that there are within-group differences in cancer risk among Blacks (414). This review also clearly demonstrated the need to disaggregate Africa in cancer studies. To reduce cancer disparity and achieve equity in treatment outcomes, cancer genetics and genomics studies in African should endeavor to stratify populations by their ancestry roots, tribes, or languages rather than countries. This is imperative to identifying population-relevant genetic variants since African countries are geopolitical constructs that bear no relationship with the biological relatedness of the people that are clustered together in those countries.

Furthermore, every genomic study requires a reference to make an appropriate inference, but African populations are presently inadequately represented in the current reference genomes. To address this unmet need, Shermanet al. (415) recently published a pan-African reference genome. The African Pan Genome sequences they assembled revealed that up to 10% of the genome will be missed by any efforts relying only on GRCh38 to study human variation. Yet, it is important to note that their study only included representative samples (5%) from Ibadan, Nigeria, and may not be a true “Pan African Genome” and may best represent the West African human population, which the Yoruba people belong to. Further research efforts are, therefore, needed to assemble more African reference genomes, which should be based on the genetic divergence of human populations in Africa.

**AUTHOR CONTRIBUTIONS**

BS conceived, designed, and supervised the review. SR and OR collected and analyzed the data. BS, SR, and OR wrote the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

Fulbright Visiting Scholar Fellowship (Grant ID: E0604356) awarded to SR.

**REFERENCES**

1. Organization WH. Global Health Observatory: Non-communicable diseases mortality and morbidity. (2013). Available at: https://www.who.int/docs/default-source/who-hsi-13-1-eng.pdf.
2. Bray F, Ferlay J, Soerjomataram I, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492
3. Walsh R, Goh B-C. Population diversity in oncology drug responses and implications to drug development. Chin Clin Oncol (2019) 8(3):3. doi: 10.21037/cco.2019.05.01
4. Teh BT. The importance of including diverse populations in cancer genomic and epigenomic studies. Nat Rev Cancer (2019) 19(7):361–2. doi: 10.1038/s41568-019-0158-0
5. Haiman CA, Stram DO. Exploring genetic susceptibility to cancer in diverse populations. Curr Opin Genet Dev (2010) 20(3):350–5. doi: 10.1016/j.gde.2010.02.007
6. Tishkoff SA, Reed FA, Friedlaender FR, Ehlert C, Ranciaro A, Froment A, et al. The genetic structure and history of Africans and African Americans. Science (2009) 324(5930):1035–44. doi: 10.1126/science.1172257
7. Lachance J, Vernot B, Ferwerda B, Froment A, Bodo JM, et al. Evolutionary history and adaptation from high-coverage whole-genome sequences of diverse African hunter-gatherers. Cell (2012) 150(3):457–69. doi: 10.1016/j.cell.2012.07.009
8. Campbell MC, Hirbo JB, Townsend JP, Tishkoff SA. The peopling of the African continent and the diaspora into the new world. Curr Opin Genet Dev (2014) 29:120–32. doi: 10.1016/j.gde.2014.09.003
9. Tucci S, Akey JM. The long walk to African genomics. Genome Biol (2019) 20(1):120. doi: 10.1186/s12859-019-1740-1
10. Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, et al. Integrated analysis of genetic ancestry and genomic alterations across cancers. Cancer Cell (2018) 34(4):549–60.e9. doi: 10.1016/j.ccell.2018.08.019
11. Quach H, Quintana-Murci L. Living in an adaptive world: Genomic dissection of the genus Homo and its immune response. J Exp Med (2017) 214(4):877–94. doi: 10.1084/jem.20161942
12. Schlehuber CM, Malmstrom H, Gunther T, Sjodin P, Coutinho A, Edlund H, et al. Southern African ancient genomes estimate modern human divergence to 350,000 to 260,000 years ago. Science (2017) 358(6363):652–5. doi: 10.1126/science.aao6266
13. Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature (2015) 517(7534):327–32. doi: 10.1038/nature13997
14. Gurdasani D, Barroso I, Zeggini E, Sandhu MS. Genomics of disease risk in globally diverse populations. Nat Rev Genet (2019) 20(9):520–35. doi: 10.1038/s41576-019-0144-0
15. Peprah E, Wiley K, Sampson U, Narula J. A new age for african-driven genomics research: human heredity and health in Africa (H3Africa). Glob Heart (2017) 12(2):67–8. doi: 10.1016/j.gheart.2017.05.003
16. Mao Y, Lu Z. MeSH Now: automatic MeSH indexing at PubMed scale via learning to rank. J Biomed Semantics (2017) 8(1):15. doi: 10.1186/s13326-017-0123-3
17. Kovalchik S. RISm렉 download content from NCBI databases. R package version, Vol. 2. (2015).
18. Rani J, Ramachandran S. pubmed: mineR: An R package with text-mining algorithms to analyse PubMed abstracts. J Biocinfo (2015) 40(4):671–82. doi: 10.1007/s12038-015-9552-2
19. Acharya A, Li S, Liu X, Pelcos G, Ziebolz D, Matthaeos N. Biological links in periodontitis and rheumatoid arthritis: Discovery via text-mining PubMed abstracts. J Periodontal Res (2019) 54(4):318–28. doi: 10.1111/jre.12632
33. Saleh EM, Wahab AH, Elhouseini ME, Eisa SS. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast and ovarian cancers. Front Biosci (Landmark Ed) (2014) 19:605–18. doi: 10.2741/4230

36. Mabrouk I, Baccouche S, El-Abed R, Mokdad-Gargouri R, Mosbah A, Said S, Mokhtari AM, et al. Minor role for BRCA2 (exon11) and p53 (exon 5-9) among Tunisian women with triple negative breast cancer. J Egypt Natl Canc Inst (2004) 16(1):62 doi: 10.1007/s10053-004-0065-4

50. Pegoraro RJ, Moodley M, Rom L, Chetty R, Moodley J. P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian malignancies in black South Africans. Int J Gynecol Cancer (2003) 13(4):133–8 doi: 10.1002/ijg.13333.x

90. doi: 10.1080/15216540400010834

95. doi: 10.1002/ijc.27326

99. doi: 10.1007/s10549-006-9303-z

82. doi: 10.1002/ijc.20186

100. doi: 10.2741/212-362

103. doi: 10.1186/s13053-017-0085-6

106. doi: 10.1007/s10689-007-0195-5

109. doi: 10.1002/ijc.22346

112. doi: 10.1111/j.1399-0004.2010.01617.x

115. doi: 10.1002/ijc.20189

118. doi: 10.7150/tcrm.212540

121. doi: 10.1002/ijc.313808.7830329

124. doi: 10.1186/s41467-018-06616-0

127. doi: 10.7573/dic.212540

130. doi: 10.3233/bd-130348

133. doi: 10.4161/cbt.3.10.11368

136. doi: 10.7150/annals.1299.137

140. doi: 10.1038/s41467-018-06616-0

143. doi: 10.3233/bd-130348

146. doi: 10.1007/s10549-012-1115-1

149. doi: 10.1186/1471-2105-7-6

152. doi: 10.1007/s00439-001-0615-0

155. doi: 10.1111/j.1399-0004.2010.01617.x

158. doi: 10.1002/ijc.20186

161. doi: 10.1186/1471-2105-8-1

164. doi: 10.7150/tcrm.212540

167. doi: 10.1002/ijc.20189

170. doi: 10.7150/tcrm.212540

173. doi: 10.1002/ijc.20189

176. doi: 10.7150/tcrm.212540

180. doi: 10.7150/tcrm.212540

183. doi: 10.7150/tcrm.212540

186. doi: 10.1111/j.1399-0004.2010.01617.x

190. doi: 10.1002/ijc.20189

193. doi: 10.1080/15216540400010834

196. doi: 10.1002/ijc.20189

199. doi: 10.1186/1471-2105-8-1

202. doi: 10.7150/tcrm.212540

205. doi: 10.1002/ijc.20189

208. doi: 10.1186/1471-2105-7-6
These lines seem to be a collection of references or bibliographic entries, possibly extracted from a scientific or medical article. Without additional context, it's challenging to provide a meaningful summary or interpretation of the content. However, I can tell you that these entries are likely discussing studies related to cancer genetics, specifically regarding BRCA1 and BRCA2 mutations in various populations around the world. The references span a range of topics, including the prevalence of mutations in different ethnic groups, the role of these mutations in cancer risk, and attempts to characterize the impact of these mutations in the specific populations studied. Each entry includes details such as the year of publication, the title of the publication, and the names of the authors, indicating a thorough and methodical research approach in the field of cancer genetics.
130. Al Azhary NM, Kamil MM, Ismail YM, Mahmoud AA, Radwan EM. The Role of Genetic Polymorphisms in Nrf2 and PT3 in Egyptian Women with Breast Cancer. Asian Pac J Cancer Prev (2016) 17(11):4945–9. doi: 10.22334/ APJC.2016.11.4945

131. Welsh J. Function of the vitamin D endocrine system in mammary gland and breast cancer. Mol Cell Endocrinol (2017) 453:88–95. doi: 10.1016/j. ymce.2017.04.026

132. Hardiman G, Savage SJ, Hazard ES, Wilson RC, Courtney SM, Smith MT, et al. Systems analysis of the prostate transcriptome in African-American men compared with European-American men. Pharmacogenomics (2016) 17 (10):1129–43. doi: 10.2174/13892036-201604-0025

133. El-Shorbagy HM, Mahmoud NH, Sabet S. Association of vitamin D receptor gene polymorphisms with breast cancer risk in Egyptian population. Tumour Biol (2017) 39(10):1–9. doi: 10.1016/j. jpmc.2017.04.026

134. Ahmed JH, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, et al. Leptin receptor Gln223Arg polymorphism and breast cancer risk in Ethiopian women. Tumour Biol (2017) (6):2313.

135. Wang S, Huo D, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, et al. Genetic variation in the vitamin D related pathway and breast cancer risk among postmenopausal Egyptian women. Tumour Biol (2015) 36(8):6425–31. doi: 10.1007/s13277-015-3332-2

136. Ben Nejima D, Ben Zarkouna Y, Gammoudi A, Manai M, Boussen H. Common matrix metalloproteinase-2 gene variants and altered expression and polymorphism of micro-RNA according to body mass index and breast cancer presentation in Tunisian patients. J Oncol (2018) 53(6):2745–57. doi: 10.3892/ jo.2018.4589

137. 31. Shaker OG, Senousy MA. Association of SNP-SNP interactions between polymorphisms and breast cancer risk among postmenopausal Egyptian women. Tumour Biol (2015) 36(8):6425–31. doi: 10.1007/s13277-015-3332-2

138. Ahmed JH, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, et al. Leptin receptor Gln223Arg polymorphism and breast cancer risk in Ethiopian women. Tumour Biol (2017) (6):2313.

139. Wang S, Huo D, Ogundiran TO, Ojengbede O, Zheng W, Nathanson KL, et al. Genetic variation in the vitamin D related pathway and breast cancer risk among postmenopausal Egyptian women. Tumour Biol (2015) 36(8):6425–31. doi: 10.1007/s13277-015-3332-2

140. Okobia MN, Bunker CH, Garte SJ, Zmuda JM, Eezeome ER, Anyanwu SN, et al. Leptin receptor Glu235Arg polymorphism and breast cancer risk in Nigerian women: a case control study. BMC Cancer (2008) 8:338. doi: 10.1186/1471-2407-8-338

141. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN, Chouchane L. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer (2006) 6:638. doi: 10.1186/1471-2407-6-38

142. 151. Jouali F, Marchoudi N, Talbi S, Bilal B, El Khasmi M, Rahihi H, et al. Detection of PIK3/ AKT pathway in Moroccan population with triple negative breast cancer. BMC Cancer (2018) 18(1):900. doi: 10.1186/ s12885-018-4811-x

143. 31. Shaker OG, Senousy MA. Association of SNP-SNP interactions between polymorphisms and breast cancer risk among postmenopausal Egyptian women. Tumour Biol (2015) 36(8):6425–31. doi: 10.1007/s13277-015-3332-2

144. Shaker OG, Senousy MA. Association of SNP-SNP interactions between polymorphisms and breast cancer risk among postmenopausal Egyptian women. Tumour Biol (2015) 36(8):6425–31. doi: 10.1007/s13277-015-3332-2

145. Shaher OG, Senousy MA. Association of SNP-SNP interactions between polymorphisms and breast cancer risk among postmenopausal Egyptian women. Tumour Biol (2015) 36(8):6425–31. doi: 10.1007/s13277-015-3332-2

146. Rahouj J, Shitti Y, Toul N, Larauqi A, Ibrahim A, Rhrab B, et al. The single nucleotide polymorphism +396 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Med Oncol (2014) 31(12):336. doi: 10.1007/s12032-014-0336-6

147. Rahouj J, Larauqi A, Shitti Y, Toul N, Ibrahim A, Ghrab B, et al. Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case-control study. Med Oncol (2014) 31(9):193. doi: 10.1007/s12032-014-0193-3
hepatocellular carcinoma using a novel cell-free DNA. Ann Hepatol (2008) 7(4):339–44. doi: 10.11656/2681(19)31834-4
200. Kirk GD, Camus-Randon AM, Mendy M, Goedert J, Merie P, Trepo C, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst (2000) 92(2):148–53. doi: 10.1093/jnci/92.2.148
201. Kimbi GC, Kew MC, Yu MC, Arakawa K, Hodkinson J. 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2005) 20(8):1185–90. doi: 10.1111/j.1440-1746.2005.03951.x
202. Kirby GM, Batist G, Fotouhi-Ardakani N, Nakazawa H, Yamasaki H, Kew M, et al. Allele-specific PCR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis. Int J Cancer (1996) 68(1):21–3. doi: 10.1002/(sici)1097-0215(19960927)68:1<21::aid-ijc7>3.0.co;2-z
203. Marchio A, Amougou Atsama M, Bere A, Komas NP, Noah Noah D, Kimbi GC, Kew MC, Yu MC, Arakawa K, Hodkinson J. 249ser p53 mutation in cell-free DNA of middle African patients with hepatocellular carcinoma. Clin Exp Med (2018) 18(3):421–31. doi: 10.1177/10238-018-0502-9
204. Ndububa DA, Yakicier CM, Ojo OS, Adeodu OO, Rotimi O, Ogunbiyi O, Kirby GM, Batist G, Fotouhi-Ardakani N, Nakazawa H, Yamasaki H, Kew M, et al. Evaluation of Mir-224, Mir-215 and Mir-143 as serum biomarkers for HCV associated hepatocellular carcinoma. Asian Pac J Cancer Prev (2017) 18(11):3167–71. doi: 10.22034/ajpcp.2017.11.3167
205. El-Abd NE, Fawzy NA, El-Sheikh SM, Soliman ME. Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol Diagn Ther (2015) 19(4):213–20. doi: 10.1007/s40291-015-0148-1
206. Motawi TM, Sadik NA, Shaker OG, Ghaele MH. Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer. Tumour Biol (2016) 37(7):9865–74. doi: 10.1007/s13277-016-4884-6
207. Motawi TM, El-Maraghy SA, Sabry D, Mehana NA. The expression of long non coding RNA genes is associated with expression with polymorphisms of HCV SERPINE1 rs7763881 and MALAT1 rs619586 in hepatocellular carcinoma and HBV Egyptian patients. J Cell Biochem (2019) 120(9):14456–55. doi: 10.1002/jcb.28276
208. Darwish WS, Ikenaka Y, Nakayama SM, Ishizuka M. An overview on mycotoxin contamination of foods in Africa. J Vet Med Sci (2014) 76(6):789–97. doi: 10.1292/jvms.13-0563
209. Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet (2008) 371(9610):367–8. doi: 10.1016/S0140-6736(08)60181-6
210. Mupunga I, Mngqawa P, Katerere DR. Peanuts, Aflatoxins and undernutrition in children in sub-saharan Africa. Nutrients (2017) 9(12):1287. doi: 10.3390/nu9121287
211. Mubomba DM, Rebeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2009) 18(7):1721–9. doi: 10.1158/1055-9965.epi-07-0675
212. Muboucha RS, Pruzzo T, Lethu T, Jenabian MA, Meye JF, Belce L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Rev Anti Infect Ther (2017) 15(6):613–27. doi: 10.1080/14787924.2017.1329202
213. McKay J, Tenet V, Franceschi S, Chabrier A, Gheit A, Gaborieau V, et al. Immuno-related polymorphisms and cervical cancer risk: The IARC
multicentric case-control study. PloS One (2017) 12(5):e0177775.
doi: 10.1371/journal.pone.0177775

237. Chatterpadhyay K. A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet (2011) 17(3):132–44. doi: 10.4103/0971-6866.92087

238. de Araujo Souza PS, Villa LL. Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat Res (2003) 544(2-3):375–83. doi: 10.1016/j.mrrev.2003.06.013

239. Laihne AO, Baba H, Bensghir R, Faysal N, Mouaïdi M, Marlah I, et al. TP53 R72P polymorphism and susceptibility to human papillomavirus infection among women with human immunodeficiency virus in morocco: a case-control study. J Cancer Prev (2017) 22(4):248–53. doi: 10.15430/JCP.2017.22.4.248

240. Ndube R, Dem A, Mbaye PM, Gueye PM, Diop G, Diop PA, et al. [Study of codon 72 of p53 gene as a risk-factor in cervical cancer in Senegal]. Bull Cancer (2014) 101(9):789–94. doi: 10.1684/bdc.2014.1911

241. Eltahir HA, Elhassan AM, Ibrahim ME. Contribution of retinoblastoma to cervical cancer. BMC Med Res Methodol (2012) 6(4):3. doi: 10.3892/mmr.2012.942

242. El kharir MM, Ennaji MM, El kebajj R, Mhand RA, Attaelje M, El Mizbri M. p53 codon 72 polymorphism and risk of cervical carcinoma in Moroccans. Med Oncol (2010) 27(3):861–6. doi: 10.1111/j.1235-0099-2009-00766.x

243. Feng Q, Hawes SE, Stern JE, Dem A, Sow PS, Dembele B, et al. Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2007) 16(6):1178–84. doi: 10.1158/1055-9966.EPI-06-0694

244. Govan VA, Loubser S, Saleh D, Hofman M, Williamson AL. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency. Int J Immunogenet (2007) 34(3):213–7. doi: 10.1111/j.1744-313X.2007.00678.x

245. Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst (2005) 97(4):273–82. doi: 10.1093/jnci/djh041

246. Arbel-Alon S, Menscer J, Feldman N, Glezerman M, Yeremian L, Friedman E. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer (2002) 12(6):741–4. doi: 10.1046/j.1525-1438.2002.01124.x

247. Tan SC, Ankathil R. Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes. Tumour Biol (2015) 36(9):6633–44. doi: 10.1007/s13277-015-3868-2

248. Zidi S, Gazouani E, Stayoussef M, Mezlini A, Ahmed SK, Yacoubi-Loueslati D, et al. The first molecular screening of MLH1 and MSH2 genes in moroccan cervical cancer patients shows a relatively high mutational prevalence. Genet Test Mol Biomarkers (2018) 22(8):492–7. doi: 10.1089/gtmb.2018.0067

249. Abdelmaksoud-Damakk R, Miladi-Abdennadher I, Amouri A, Tahri N, Ayadi L, Khabir A, et al. High prevalence of the c.1227_1228dup –72P polymorphism and susceptibility to human papillomavirus infection among black Africans and the Mixed Ancestry population of South Africa. J Cancer Prev (2017) 61(3):214–7. doi: 10.1034/j.1399-0004.2002.610308.x

250. Ramesar RS, Madden MV, Felix R, Harocopos CJ, Westbrook CA, Jones G, et al. Molecular genetics improves the management of hereditary non-polyposis colorectal cancer. S Afr Med J (2000) 90(7):709–14.

251. Elsaid A, Elshazli R, El-Tarapely F, Darwish H, Abdel-Malak C. Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer. Fam Cancer (2017) 16(1):83–90. doi: 10.1007/s10689-016-9927-x

252. Laarabi FZ, Cherkaoui Jaoaud I, Baert-Desurmont S, Ouldik K, Ibrahim I, Kanoui N, et al. The first mutations in the MYH gene reported in Moroccan colon cancer patients. Gene (2012) 496(1):55–8. doi: 10.1016/j.gene.2011.12.024

253. Laarabi FZ, Cherkaoui Jaoaud I, Benazzou A, Squalli D, Señan A. Prevalence of MYH-associated polyposis related to three recurrent mutations in Morocco. Ann Hum Biol (2011) 38(3):360–3. doi: 10.3109/03014460.2010.521520

254. Moussa SA, Moussa A, Kourda N, Mezlini A, Abdellé N, Zerimech F, et al. Lynch syndrome in Tunisia: first description of clinical features and germline mutations. Int J Colorectal Dis (2011) 26(4):455–67. doi: 10.1007/s00384-010-1129-9

255. Hitchins MP, Owens SE, Kwok CT, Godmark G, Algar UF, Ramesar RS. Identification of new cases of early-onset colorectal cancer with an MLH1 epimutation in an ethnically diverse South African cohort. Clin Genet (2011) 80(5):428–34. doi: 10.1111/j.1399-0004.2011.01660.x

256. Meinhof A, Bouguenouch L, El Bouchikhi I, Chbani L, Iraqui Houssaini M, Sekal M, et al. The first molecular screening of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women. J Clin Lab Anal (2009) 23(6):343–7. doi: 10.1002/jcla.20198

257. Ziada-Bouchaar H, Sfi K, Filali T, Hammadna T, Satta D, Abadi N. First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome. Fam Cancer (2017) 16(1):57–66. doi: 10.1007/s10689-016-9917-1

258. Faissi-Ben Moussa S, Moussa A, Lovecchio T, Kourda N, Najjar T, Ben Jilani S, et al. Identification and characterization of a novel MLH1 genomic rearrangement as the cause of HNPCC in a Tunisian family: evidence for a homologous Alu-mediated recombination. Fam Cancer (2009) 8(2):119–26. doi: 10.1007/s10689-008-9215-7

259. Moufd FZ, Bouguenouch L, El Bouchikhi I, Houssaini M, Ouldik D. Molecular and presymptomatic analysis of a Moroccan Lynch syndrome family revealed a novel frameshift MLH1 germline mutation. Turk J Gastroenterol (2018) 29(6):701–4. doi: 10.5152/tjg.2018.17761

260. El-Serafi MM, Bahmassy AA, Ali NM, Eid SM, Kamel MM, Abdel-Hamid NA, et al. The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer (2010) 116(21):4954–64. doi: 10.1002/cncr.25417

261. Karim B, Florence C, Kamel R, Nadia K, Ines O, Raja M, et al. KRAS mutation detection in Tunisian sporadic colorectal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography. Cancer Biomark (2010) 8(6):331–40. doi: 10.3233/CBM-2010-0222

262. Ines C, Donia O, Rahma B, Ben Ammar A, Sameh A, Khalfallah T, et al. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort. Tumour Biol (2014) 35(7):7163–75. doi: 10.1007/s13277-014-1874-4

263. Marchoudi N, Amrani Hassan Joutei H, Jouali F, Fekkah J, Raihiss H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol (Paris) (2013) 61(6):273–6. doi: 10.1016/j.pathbio.2013.05.004

264. Raskin L, Dakubo JC, Palaski N, Greenem JK, Gruber SB. Distinct molecular features of colorectal cancer in Ghana. Cancer Epidemiol (2013) 37(5):556–61. doi: 10.1016/j.canep.2013.07.007
306. Rafrafi A, Kaabachi S, Kaabachi W, Chahed B, Amor AB, Mbarik M, et al. CCR2-64I polymorphism is associated with non-small cell lung cancer in Tunisian patients. *Hum Immunol* (2015) 76(5):348–54. doi: 10.1016/j.jhimmun.2015.03.003

307. Kaabachi W, Kaabachi S, Rafrafi A, Amor AB, Tizaoui K, Haj Sassi F, et al. Association of vitamin D receptor Fok1 and Apol polymorphisms with lung cancer risk in Tunisian population. *Mol Biol Rep* (2014) 41(10):6545–53. doi: 10.1007/s11033-012-3558-2

308. Kaabachi W, ben Amor A, Kaabachi S, Rafrafi A, Amor AB, Tizaoui K, Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. *Cytokine* (2014) 66(1):23–9. doi: 10.1016/j.cyto.2013.12.012

309. Kaabachi S, Kaabachi W, Rafrafi A, Belkas H, Hamzaoui K, Sassi FH. Tumor necrosis factor gene polymorphisms in Tunisian patients with non-small cell lung cancer. *Clin Lab* (2013) 59(11-12):1389–95. doi: 10.7754/clinlab.2013.10016

310. Rafrafi A, Chahed A, Kaabachi S, Kaabachi W, Maalhi M, Hamzaoui K, et al. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: A case control study. *Hum Immunol* (2013) 74(10):1368–74. doi: 10.1016/j.jhimmun.2013.06.033

311. Haroun RA, Zakhary NI, Mohamed MR, Abdelrahman AM, Kandil EI, Shalaby KA. Assessment of the prognostic value of methylation status and expression levels of FHT, GSTP1 and p16 in non-small lung cancer in Egyptian patients. *Asian Pac J Cancer Prev* (2015) 15(10):4281–7. doi: 10.7314/APJCP.2015.15.10.4281

312. Hetta HF, Zahran AM, El-Mahdy RI, Nabil EE, Elsmael HM, Elkady OA, et al. Assessment of circulating miRNA-17 and miRNA-222 expression profiles as non-invasive biomarkers in Egyptian Ptspts with non-small-cell lung cancer. *Asian Pac J Cancer Prev* (2019) 20(6):1927–33. doi: 10.31557/APJCP.2019.20.6.1927

313. Michaud DS. Chronic inflammation and bladder cancer. *Urol Oncol* (2007) 25(3):260–8. doi: 10.1016/j.urolonc.2006.10.002

314. Rosin MP, Anwar WA, Ward AJ. Role of inflammation, chromosomal instability, and cancer: the schistosomiasis model. *Cancer Res* (1994) 54(7 Suppl):1929s–33s.

315. Shams TM, Metawe M, Salim EL. c-KIT positive schistosomiasis urinary bladder carcinoma are frequent but lack KIT gene mutations. *Asian Pac J Cancer Prev* (2013) 14(1):15–20. doi: 10.7314/apjcp.2013.14.1.15

316. Bowa K, Mulele C, Kachimba J, Manda E, Mapulanga V, Mukosai S. A review of bladder cancer in Sub-Saharan Africa: A different disease, with a distinct presentation, assessment, and treatment. *Ann Afr Med* (2018) 17(3):99–105. doi: 10.4103/aam.aam_48_17

317. Elsaa S, Ahmed MI, Said H, Zaghlool A, El-Ahmady O. Cell cycle regulators in bladder cancer: relationship to schistosomiasis. *J UMBM Life* (2004) 56(9):537–64. doi: 10.1080/15216540400013903

318. Adenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. *Br J Infect Dis* (2015) 192(1):196–205. doi: 10.7314/abp.2014.11.004

319. Shaw ME, Elder PA, Abbas A, Knowles MA. Partial allelotype of schistosomiasis-associated bladder cancer. *Int J Cancer* (1999) 80(5):656–61. doi: 10.1002/(sici)1097-0215(19990301)805:66-65/aed-ijdj-c-3-0.0.co;2-a

320. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. *Cancer Res* (1993) 53(6):3795–9.

321. Feki-Tounsi M, Khli Y, Settou I, Fourati M, Mhiri MN, Hamza-Chaffai A, et al. Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population. *Environ Sci Pollut Res Int* (2017) 24(28):22476–84. doi: 10.1007/s11356-017-9767-x

322. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Ghoneim MA, Au WW. The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. *Cancer Lett* (1997) 119(1):115–22. doi: 10.1016/s0304-3835(97)00026-5

323. Ouerni S, Marrakchi R, Bougharet K, Riadh Ben Slama M, et al. Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors. *Cancer Invest* (2009) 27(10):998–1007. doi: 10.1080/07357900902849707
Rotimi et al. Cancer Genetics and Genomics in Africa

345. Tamimi Y, Bringuer PP, Smit F, van Bokhoven A, Abbas A, Debruyne FM, et al. Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer. Int J Cancer (1996) 68(2):183–7. doi: 10.1002/(SICI)1097-0215(19960902)68:2<183:AID-IJC7-3.0.CO;2-U

346. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K. Cpg island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mod Pathol (2004) 17(10):1268–74. doi: 10.1038/modpathol.3800177

347. Motawi TK, Rizk SM, Ibrahim TM, Ibrahim IA. Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis. Cell Biochem Funct (2016) 34(3):142–8. doi: 10.1002/cbf.3517

348. Zhong X, Isharwal S, Naples JM, Shiff C, Veltri RW, Shao C, et al. Genetic aberrations of the K-ras proto-oncogene in bladder cancer in a Tunisian population. Infect Agent Cancer (2011) 6:55. doi: 10.1186/13027-016-0104-7

349. Ayadi W, Feki I, Khabir A, Boudawara T, Ghorbel A, Charfeddine I, et al. Polymorphism analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from Tunisian patients. Virus Genes (2007) 34(2):137–45. doi: 10.1007/s11262-006-0051-2

350. Bahnassy AA, Zeki AR, Asaad N, El-Houssini S, Khalid HM, Sedky LM, et al. Epstein-Barr viral infection in extranodal lymphoma of the head and neck: correlation with progression and response to treatment. Histopathology (2006) 48(5):516–28. doi: 10.1111/j.1365-2559.2006.02373.x

351. Malik MO, Banatvala J, Hutt MS, Abu-Sin AJ, Hidayatallah A, El-Had AE. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report. J Natl Cancer Inst (1979) 62(2):221–4.

352. Hadhri-Guiga B, Khabir AM, Mokdad-Gargouri R, Ghorbel AM, Drira M, Ayadi W, Feki L, Khabir A, Boudawara T, Ghorbel A, Charfeddine I, et al. The role of chromosomal aberrations in Kenyan Wilms Tumor. Genes Chromosomes Cancer (2015) 54(11):702–15. doi: 10.1002/gcc.22281

353. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el SK, Salem FK. Cytokine gene polymorphisms in Egyptian cases of low grade glioma. PloS One (2014) 9(7):e103432. doi: 10.1371/journal.pone.0103432

354. Taha H, Yehia M, Mahmoud M, El-Beltagy M, Ghabriel M, El-Naggar S. Incidence of kiaa1549-brad fusion gene in Egyptian pediatric low grade glioma. Clin Transl Med (2015) 4:10. doi: 10.1186/s40169-015-0052-7

355. Lazarus P, Idris AM, Kim J, Calcagnotto A, Hoffmann D. p53 mutations in head and neck squamous cell carcinomas from Sudanese snuff (toombak) users. Cancer Detect Prev (1996) 20(4):270–8.

356. Ibrahim SO, Vasstrand EN, Johannessen AC, Idris AM, Magnusson B, Lazarus P, Idris AM, Kim J, Calcagnotto A, Hoffmann D. p53 mutations in head and neck cancer in Tunisia. Int J Cancer (2004) 115(1):24–30. doi: 10.1002/ijc.20035

357. Taha H, Yehia M, Mahmoud M, El-Beltagy M, Ghabriel M, El-Naggar S. Incidence of kiaa1549-brad fusion gene in Egyptian pediatric low grade glioma. Clin Transl Med (2015) 4:10. doi: 10.1186/s40169-015-0052-7

358. Settin A, Ali N, Salem FK. Cytokine gene polymorphisms in Egyptian cases of low grade glioma. PloS One (2014) 9(7):e103432. doi: 10.1371/journal.pone.0103432

359. Tawdy MH, Abd El Nasser MM, Abd El Shafy SS, Nada MA, El Sraify MN, Magd AH. Role of serum TRAIL level and TRAIL apoptosis gene expression in multiple sclerosis and relation to brain atrophy. J Clin Neurosci (2014) 21(9):1606–11. doi: 10.1016/j.jocn.2013.11.056

360. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el SK, Salem FK. Cytokine gene polymorphisms in Egyptian cases with brain tumors. J Egypt Natl Canc Inst (2009) 21(2):101–6.

361. Settin A, Ali N, Salem FK. Cytokine gene polymorphisms in Egyptian cases with brain tumors. Egypt J Immunol (2008) 15(2):15–23.

362. Benenemissi IH, Sif K, Sahli LK, Semmam O, Abadi N, Satta D. Angiotensin-converting enzyme insertion/deletion gene polymorphisms and the risk of glioma in an Algerian population. Pan Afr Med J (2019) 32:197. doi: 10.11604/pamj.2019.32.197.15129

363. Hilmani S, Abidi O, Benrahma H, Karkouri M, Sahraoui S, El Azzari H, et al. Clinicopathological features and molecular analysis of primary glioblastomas in Moroccan patients. J Mol Neurosci (2013) 49(3):567–73. doi: 10.1007/s12031-012-9684-4

364. Senhaji N, Louati S, Chbani L, Bardai SE, Mikou K, Mokdad MG, et al. Prevalence of HD1/2 mutations in different subtypes of glioma in the...
413. Durvasula A, Sankararaman S. Recovering signals of ghost archaic introgression in African populations. Sci Adv (2020) 6(7):eaax5097. doi: 10.1126/sciadv.aax5097

414. Odedina FT, Dagne G, LaRose-Pierre M, Scrivens J, Emanuel F, Adams A, et al. Within-group differences between native-born and foreign-born Black men on prostate cancer risk reduction and early detection practices. J Immigr Minor Health (2011) 13(6):996–1004. doi: 10.1007/s10903-011-9471-8

415. Sherman RM, Forman J, Antonescu V, Puiu D, Daya M, Rafael N, et al. Assembly of a pan-genome from deep sequencing of 910 humans of African descent. Nat Genet (2019) 51(1):30–5. doi: 10.1038/s41588-018-0273-y

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Rotimi, Rotimi and Salhia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.